Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MUC1-targeted peptide GO-2-03-2C

An optimized small peptide drug candidate targeting epithelial mucin (MUC1) with antineoplastic activity. MUC1-targeted peptide GO-203-2C interacts with oncoprotein MUC1 C-terminal subunit on the cell surface, thereby impeding cell-cell interactions, signaling, and metastasis. MUC1 antigen, a membrane bound glycoprotein expressed by most glandular and ductal epithelial cells, is over-expressed in many diverse human carcinomas including those of the breast, prostate, lung, colon, pancreas, and ovary, and has been associated with poor prognosis.
Code name:GO-203-2C
Search NCI's Drug Dictionary